Mad Hedge Technology Letter
November 27, 2024
Fiat Lux
Featured Trade:
(BEST BUY THROWS UP SOME WARNING SIGNALS)
(BBY), (AAPL)

Mad Hedge Technology Letter
November 27, 2024
Fiat Lux
Featured Trade:
(BEST BUY THROWS UP SOME WARNING SIGNALS)
(BBY), (AAPL)

Best Buy (BBY) tanking their earning results is indicative of where we are right now, not only as a society but also in the tech sector.
People just don’t have that extra dollar or 2 to fund that iPhone (AAPL) upgrade, and that is why Best Buy sales are so underwhelming.
It isn’t the end of the world, but we need the consumers to stay healthy for the short-term health of the tech sector.
Sure, it is true that a great deal of spend comes from enterprise sources, but that is not the entire economy.
The U.S. economy is held up by consumers, and that isn’t the case in many other economies like China or India.
Get ready for a lukewarm Christmas season, which should manifest itself in some pretty sweet deals for the individual.
At the aggregate level, it looks quite sluggish in the mid-term as electronic retailer Best Buy ponders about how to reverse the dimming outlook.
Best Buy cut its full-year sales forecast and missed revenue targets.
Best Buy expects full-year comparable sales to decline by between 2.5% and 3.5%, compared with its prior expectations of a 1.5% to 3% drop.
Granted, the holiday season is five days shorter than last, so some of the softness is a one-off.
Management did say shoppers are responding to big deals and sales events. Management said it expects the peak in sales during times like Black Friday and Cyber Monday to be higher but the valleys before and after those to be lower.
Best Buy is waiting for a wave of shoppers to replace old devices and upgrade to new, higher-tech ones after an approximately two-year sales slump in the consumer electronics category.
Management said they anticipate this year to be one that brings “increasing industry stabilization.” They also mentioned specifically about Apple’s fresh collection of iPads, as well as artificial intelligence-enabled laptops from Microsoft, will drive sales.
Tariffs could put Best Buy’s sales at risk, too, if they result in higher costs for the company and for customers. President-elect Donald Trump said he would raise tariffs by an additional 10% on all Chinese goods and impose tariffs of 25% on imports from Mexico and Canada.
Artificial intelligence products are nowhere near the shelves of Best Buy, and nobody knows when they will debut.
A.I. continues to be strictly an enterprise build-out with a future use case, which doesn’t help companies like Best Buy and their bottom line.
Apple and its micro-improvements don’t move the needle enough for shoppers to get off the sidelines and splurge.
This type of transitory environment for consumer tech isn’t what investors like to hear.
I also mentioned earlier about the inflation effect of households redirecting funds to essentials like housing, insurance, and food.
Therefore, it is better for investors to stay out of the tech consumables and target the enterprise side of the equation.
I don’t believe the enterprise part of tech needs a reboot of growth is waning, and I am still executing bullish trades in stocks that are exposed to the A.I. story.
However, the times of the “tide lifts all boats” all long gone in the rearview mirror.
Today, I executed another bullish trade in Dell (DELL) on a monster dip of 12%. Weak guidance is another manifestation of stalling tech growth. I will exit this position before the year is over.



When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

(AUSTRALIA CHALLENGES BIG TECH BY IMPOSING SOCIAL MEDIA BANS FOR UNDER 16’s)
November 27, 2024
Hello everyone
AUSTRALIA COULD BE IN THE DOGHOUSE UNDER TRUMP’S WATCH
It seems that Donald Trump’s team finds Albanese’s move to introduce social media bans for those under 16’s a little bit “on the nose,” to say the least. So much so that Australia could find itself hit with hefty US tariffs.
Elon, who is not a stranger to sharing his views bluntly, has already slammed the move within hours of the bill being tabled. “Seems like a backdoor way to control access to the internet by all Australians.”
If the bill is passed, social media companies could be hit with fines of up to $50 million if they fail to do enough to verify a user’s age on their platforms.
The changes will impact social platforms like TikTok, Facebook, Instagram, Reddit, and X, but YouTube will be exempt.
Snapchat is also expected to come under the same Australian law.
A ban on social media won’t be a cure all. Stopping someone looking at social media will not address mental health issues by itself. It’s more complex than that.
Of course, the ban won’t stop teenagers under 16 from using social media. They will find a way to get around it.
Here’s a way to look at the ban.
There are age restrictions on alcohol. Having those restrictions in place at a certain age sets a standard.
The laws would come into force 12 months after passing, and the eSafety commissioner would be responsible for enforcing the legislation.
How they are going to enforce the legislation is not yet clear.
Ultimately, more education programs about social media need to be put in place – in schools, universities, and in workplaces – to highlight the pros and cons and understand its place and function in the world at large.
Such programs would enable parents and children to develop knowledge and awareness of how to navigate these spaces safely.
We all know that the character of people who use this channel of communication can be either destructive or helpful.
Unfortunately, those who want to inflict harm find social media facilitates their malicious intent. They hide behind their anonymity. Fake posts scammers parading around under the guise of “looking for romance” when they are really looking for the contents of your wallet. And let’s not forget your actual friend’s Facebook page being hacked by some loser who has nothing better to do. Or scammers who use Facebook to sell something or offer their trade services and then disappear after they receive the funds.
No doubt, with the advancement of AI, social media could morph into a smarter communication form, which may be able to better police and eradicate the “wolves in sheep’s clothing,” or at least “red flag” the post.
My 19-year-old son only uses Instagram occasionally; he doesn’t use any other social media platforms. Discord is his platform of choice to communicate with friends.
Social media platforms should be held accountable for making sure their platform is a safe space to use.
Equally important is educating users about how to safely traverse these platforms so mental health issues do not dominate their lives.


QI CORNER

SOMETHING TO THINK ABOUT

HOUSEKEEPING
Apologies for the late arrival of the October Zoom meeting recording. It is still being edited. The November Zoom monthly meeting will be held early next week. Zoom links will be sent out in the next couple of days.

And

Cheers
Jacquie
Global Market Comments
November 27, 2024
Fiat Lux
Featured Trade:
(THE REAL ESTATE CRASH COMING TO A MARKET NEAR YOU),
(THE FALLING MARKET FOR KIDS)

Hardly a day goes by when a reader doesn’t ask me when the Australian real estate bubble is going to burst.
They are right to be concerned.
In the table below, Sydney is ranked as the second most expensive market in the world at 12.2 times the local median pre-tax household annual income.
It is far behind Hong Kong, at 19.9 times, and just ahead of Vancouver, Canada, at 10.8 times.
Even Australian banking regulators are concerned about a “Dutch tulip” style mania developing in the Land Down Under.
They are worried that the coming price collapse will pose a major threat to their financial system.
Indeed, a home on Sydney Harbor owned by my former employer, the Fairfax newspaper family, sold for a staggering AUS$75 million, a new record for the country.
Sure, the views are great. But AUS$75 million?
I have been through a lot of these real estate booms over the past five decades.
There was the notorious Japanese bubble in 1990. I have been through at least three such booms in California. Here, real estate brokers can turn into Uber drivers in a heartbeat.
And they always follow the same predictable pattern.
How high is high? Think of an absurd, impossible number, and then double it. That always seems to be a good rule of thumb. Except that Australia is already past that last doubling.
When my Australian friends ask how high prices can go, I tell them to check out prices in Shanghai, where apartments go for twice as high for a quarter of the space.
In fact, identifying bubble tops is a fool’s errand. When markets become irrational, the last thing buyers care about is rationality, hard data, or valuations.
In the past, the music always stopped playing for the same reasons.
Central banks fearful of inflation slammed on the brakes and drove interest rates through the roof, as Paul Volker did in 1980.
An extraneous shock, such as the 1973 and 1979 oil price spikes or the 1991 Savings & Loan Crisis, can also let the air out of the balloon.
I remember that during the S&L Crisis, I was ushered in to see a California property, and the owner burst into tears when the agent mentioned the price because of the huge personal hit he was taking on his equity.
Except that this time, it’s different.
Real estate used to be local. Now, it’s global.
You have the same factor pushing up property in prime markets all over the world at the same time: Chinese buying.
For a decade now, buyers from the Middle Kingdom have been bidding up the prices of homes in London, Australia, New York, Vancouver, and elsewhere.
You know that nice little mansion I sold in London in 1994 for $2 million? It’s now worth $20 million.
In nearby Napa Valley, CA, the Chinese are snapping up trophy vineyards left and right, paying wildly inflated prices. Prices are up an eye-popping 16.6% year on year.
You can always tell when a property changes hands when the stone lions show up at the front gates.
Their goal is the same everywhere. Get their money out of China before the wheels fall off, be it for economic or political reasons.
The Chinese aren’t looking for retirement homes. They need bolt-hole places to hide out.
A stepped-up anti-corruption campaign by the Beijing government seems to have accelerated the trend.
The capital flows have been so enormous that the Chinese government has had to liquidate $1 trillion in foreign exchange reserves, a quarter of the total, primarily held in US Treasury bonds, notes, and bills, to support the Renminbi.
These gargantuan capital flows have created the same anomalies around the world, that of “ghost neighborhoods” owned for investment purposes only.
On the receiving end, the US government is taking measures to stem money laundering and tax evasion.
The IRS is using the Patriot Act to require proof of ownership for all real estate purchases over $2 million in New York and San Francisco.
Cayman Islands, British Virgin Islands, and Cook Islands nominee holding companies or LLC’s can no longer be used as identity shields.
Without real residents living there, local businesses, like dry cleaners, coffee shops, and supermarkets, die off for lack of customers.
Take a walk around the Mayfair district of London one of these days, and you’ll see what I mean.
Or ride up and down the elevators in the residential towers at New York’s Columbus Circle, where 60% of the apartments are foreign-owned.
I even have one of these at the end of my street here in San Francisco.
The home came on the market for $2.1 million three years ago and sold in a day for $2.3 million. It has been empty ever since.
(By the way, the opposite end of my street displays San Francisco’s other big problem, start-ups moving into cheaper residences to avoid sky-high commercial property rates. There, the lights NEVER go out.)
Real estate agents everywhere love the business.
Most of these deals are done for cash only with rushed due diligence. Loan approvals and appraisals, frequent deal killers for domestic buyers, never even enter the picture.
For the sake of full disclosure, I have to admit that I have been a happy participant in the property gold rush like everyone else, making a kings ransom on properties I bought during the 2011 bottom, at least on paper.
Look at the table below, and you’ll see that four of the world’s ten most expensive cities are in California. Perhaps I shouldn’t throwing stones in glass houses.
But at least here, you have multiple booms going on in technology, health care, alternative energy, and transportation, driving earnings, and, therefore, house prices.
Since the causes of this bubble are largely come from China, so must the end.
A serious economic slowdown in China would tip the balance. So would a trade war with the US.
Tougher controls on capital flows could stem the tide. So would political instability, never far below the surface in China.
Whatever the reason, leveraged owners of luxury real estate anywhere on the planet should always keep one thing in mind: Your fate is totally in the hands of China.

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more
Mad Hedge Biotech and Healthcare Letter
November 26, 2024
Fiat Lux
Featured Trade:
(NO MORE EATING AT YOU)
(PFE), (LLY), (NVO), (AMGN), (RYTM), (ALT)

In 1903, the original “diet miracle” was invented—tapeworm pills. Yes, people willingly ingested parasites to lose weight.
Thankfully, modern weight-loss drugs have evolved to become a bit more... palatable. Enter Pfizer (PFE), taking the pharmaceutical stage in Q3 2024 with a performance that’s anything but parasitic.
Pfizer just reported a stunning $17.7 billion in Q3 2024 revenue—a 31% year-over-year increase that has nothing to do with parasites and everything to do with strategic positioning.
But here's where it gets interesting. Even if you strip away Pfizer's COVID-19 products (which, let's face it, had their moment like platform shoes in the '70s), they're still sitting pretty with $13.6 billion in revenue.
That's a 14% operational increase that has nothing to do with our old friend coronavirus.
Meanwhile, in the weight-loss corner of the ring, Eli Lilly (LLY) and Novo Nordisk (NVO) are experiencing what we might delicately call "growing pains."
Eli Lilly reported $11.44 billion in Q3 revenue—impressive until you consider analysts expected $12.18 billion.
Novo Nordisk's story is even more peculiar. Their weight-loss wonder drug Wegovy is selling like hotcakes (irony noted) at 17.3 billion Danish krone (about $2.75 billion USD).
But here's the catch: Novo Nordisk can't make enough of it. It's the pharmaceutical equivalent of having a hit restaurant where half the menu items are perpetually "sold out."
This shortage highlights just how insatiable the market's appetite for these drugs has become.
In 2023 alone, the US market for prescription weight-loss drugs more than doubled from $5.1 billion to $11.9 billion.
Gone are the days of dubious diet pills and miracle cures. We're witnessing the dawn of scientifically backed weight management solutions.
As for Pfizer, they’re not content to watch from the sidelines. They're developing something called danuglipron (a name that sounds like it was conceived during a particularly intense game of Scrabble). It's an oral weight-loss drug currently in Phase 2B trials.
Danuglipron’s key selling point? It's an oral medication—no needles required.
As someone who once spent three months investigating the science of injection phobia for a story, I can confirm this detail matters more than you might think.
Pfizer’s plans go beyond just one drug. In the first 9 months of 2024, they invested $7.8 billion in R&D.
Their recent acquisition of Seagen has already contributed $854 million in Q3 2024 revenue, proving that their strategy of buying innovation is paying off.
In fact, they're so confident about their trajectory that they've raised their full-year 2024 revenue guidance to between $61 billion and $64 billion.
But let's talk about the elephant in the pharmacy – regulatory approval. The FDA, bless their bureaucratic hearts, has been keeping everyone on their toes with their evolving stance on weight-loss drugs and other treatments.
Still, Pfizer managed to snag approvals for two new drugs in October 2024: Abrysvo (for RSV in adults) and Hympavzi (for hemophilia).
Both approvals came through in October 2024, showing off Pfizer’s ability to navigate modern pharmaceutical regulations.
Looking globally, the weight loss and obesity management market is projected to grow from $14.51 billion in 2024 to $48.39 billion by 2034.
Of course, no good pharma story is complete without a plot twist. Pfizer's oncology drug Ibrance saw a 12% operational decrease in Q3 2024 revenue, reminding us that even pharmaceutical juggernauts can stub their toes.
And those patents? They're like time bombs ticking away in the legal department's filing cabinet.
The obesity field is attracting new players, too. Amgen (AMGN) is developing MariTide, while Rhythm Pharmaceuticals (RYTM) focuses on genetic obesity disorders.
Altimmune's (ALT) pemvidutide is showing promising Phase 2 results, adding to the increasingly crowded field of weight-loss treatments.
So, where should you park your money? Here’s a quick guide to the stocks worth scooping up when the market takes a breather.
Novo Nordisk remains the heavyweight champion of weight-loss drugs, with Wegovy and Ozempic bringing in the big bucks. Yes, they're wrestling with production issues, but their first-mover advantage and global reach make them a solid buy for the long haul.
Eli Lilly, with Mounjaro and the freshly minted Zepbound, deserves a spot in your portfolio too. Their supply chain headaches are likely temporary, and their pipeline is bursting with potential.
Pfizer, our surprising comeback kid, rounds out the list. They might be fashionably late to the weight-loss party, but their diversification strategy and that promising GLP-1 pill in development make them worth your investment dollars. Plus, their global reach could give them an edge against their competitors.
On the hold list, we’ve got Amgen and Rhythm Pharmaceuticals—stocks you might want to keep an eye on but not necessarily dive into headfirst just yet.
Amgen's MariTide shows promise, but they're playing in a very crowded pool. Rhythm's focus on genetic obesity disorders is fascinating, but they're like a promising indie band - they might hit it big, or they might not.
As for Altimmune and Viking Therapeutics? Sometimes you need to know when to fold 'em. Despite promising early results, they're up against giants with deeper pockets and better-established supply chains.
Unless you enjoy roller coasters without safety bars, consider redirecting those investment dollars elsewhere.
Looking back, we've come an astonishingly long way from those desperate days of tapeworm pills—turns out the real money wasn't in selling parasites, but in pioneering their prescription-strength replacements.
And that's the kind of progress that would make those 1903 tapeworm salesmen drop their jaws (and hopefully nothing else).

Global Market Comments
November 26, 2024
Fiat Lux
Featured Trade:
(TRADING THE KENNEDY ASSASSINATION)

Legal Disclaimer
There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.
